GSK’s Cervarix put backfire on MSD’s Gardasil
.jpg)
Since the government is expected to practically include cervical cancer vaccines in the National Immunization Program(NIP) business next year, GSK and MSD Korea have exchanged words over cost-effectiveness.
GSK(GlaxoSmithKline) announced the result of ‘Cervical Cancer Vaccine’s Cost Effectivenes...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
